Tickers

1. Composite Trajectory Verdict

Given NEO's high-fixed-cost diagnostic services model, the income statement (revenue growth, margin trajectory, and path to GAAP profitability) and cash flow statement (operating cash generation to fund operations and debt service) carry the most weight; the balance sheet reflects financing decisions but is secondary to operating performance.

Composite Trajectory: Mixed

The quarterly data (Q2 and H1 2026 vs. 2025) show clear improvement: revenue grew 11.2%, gross margin expanded 140–300 bps, G&A fell sharply as a percentage of revenue, net income turned positive in Q2 2026, and operating cash flow swung to $11.8 million from -$5.0 million (10-Q 2026-06-30, MD&A; Consolidated Statements of Operations; Consolidated Statements of Cash Flows). However, the annual series (2023–2025) shows deteriorating GAAP profitability despite revenue growth: net loss widened from $(78.7) million to $(108.0) million, operating loss deepened from $(92.1) million to $(115.9) million, and accumulated deficit grew to $(433.8) million (10-K 2025-12-31, Consolidated Statements of Operations; Consolidated Statements of Stockholders' Equity). Cash flow from operations was positive but declined annually ($7.0M → $5.2M), and the balance sheet shows equity erosion ($902.3M → $836.6M → $785.7M) with new convertible debt issued in 2026 (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Improving recent quarters are offset by worsening annual GAAP trends and balance sheet deterioration.

2. Red Flags

• Persistent GAAP losses despite revenue growth: Net loss widened to $(108.0) million in 2025 from $(78.7) million in 2024 on 10.1% revenue growth (10-K 2025-12-31, Consolidated Statements of Operations).
• Large, recurring impairment charges: $27.8 million in 2025 (InVisionFirst-Lung $11.4M, Trapelo disposal $15.9M, inventory $0.4M) and $20.0 million in Q2 2025, with none in 2024 or 2026 periods (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, MD&A Impairment Charges).
• Widening GAAP vs. non-GAAP gap: Adjusted EBITDA rose to $43.4 million in 2025 while GAAP net loss deepened; adjustments include $27.8M impairment, $11.3M IP litigation, $7.3M acquisition costs, $3.5M CEO transition, and $41.3M stock-based compensation (10-K 2025-12-31, MD&A Non-GAAP reconciliation).
• Regulatory matter reserve with open-ended exposure: $11.2 million accrued as of December 2025 for potential federal healthcare program liabilities; company "unable to estimate a range of possible loss in excess of the amount reserved" (10-K 2025-12-31, Note 15 Commitments and Contingencies).
• Share repurchase while generating GAAP losses: $25.0 million used to repurchase shares in H1 2026 alongside a $(14.9) million YTD net loss (10-Q 2026-06-30, MD&A Liquidity; Consolidated Statements of Operations).
• New convertible debt issuance with partial repurchase of existing notes: $305.7M 2032 Notes issued, $262.9M 2028 Notes repaid, $28.7M capped call premiums paid in H1 2026, increasing total convertible debt to $374.2M from $341.9M (10-Q 2026-06-30, MD&A Liquidity; Consolidated Balance Sheets).
• Accumulated deficit growth: $(325.8)M (2024) → $(433.8)M (2025) → $(448.7)M (Jun 2026) (10-K 2025-12-31, Consolidated Statements of Stockholders' Equity; 10-Q 2026-06-30, Consolidated Statements of Stockholders' Equity).
• Working capital decline: $288.0M (Dec 2025) → $275.6M (Jun 2026) (10-K 2025-12-31, MD&A Liquidity; 10-Q 2026-06-30, MD&A Liquidity).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual GAAP results deteriorated in 2025: revenue rose 10.1% to $727.3M but gross margin slipped to 43.2% from 43.9%, operating loss widened to $(115.9)M from $(92.1)M, and net loss deepened to $(108.0)M from $(78.7)M, driven by $27.8M impairment charges, higher compensation ($23.3M in cost of revenue, $11.5M in G&A), and $5.9M higher R&D (10-K 2025-12-31, Consolidated Statements of Operations; MD&A Results of Operations). Conversely, quarterly trends improved markedly in 2026: Q2 revenue grew 11.2% to $201.7M, gross margin jumped to 45.6% from 42.6%, G&A fell 11.3% to $63.6M (31.5% of revenue vs 39.6%), and net income reached $2.2M vs $(45.1)M; YTD net loss narrowed to $(14.9)M from $(71.0)M (10-Q 2026-06-30, MD&A Results of Operations; Consolidated Statements of Operations). Adjusted EBITDA (non-GAAP) grew annually to $43.4M from $39.6M and quarterly to $23.5M YTD from $17.7M (10-K 2025-12-31, MD&A Non-GAAP; 10-Q 2026-06-30, MD&A Non-GAAP).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Annual operating cash flow remained positive but declined: $5.2M in 2025 vs $7.0M in 2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows). The 2025 decline was driven by operating results (net loss adjusted for non-cash charges) using $2.3M more cash, partially offset by working capital changes (10-K 2025-12-31, MD&A Liquidity). Quarterly comparison shows strong improvement: H1 2026 operating cash flow was $11.8M vs -$5.0M in H1 2025, a $16.8M swing driven by $22.2M higher gross profit (10-Q 2026-06-30, MD&A Liquidity; Consolidated Statements of Cash Flows). Investing cash outflows increased to $13.3M in H1 2026 from $5.8M in H1 2025 due to lower maturities proceeds and higher capex (10-Q 2026-06-30, MD&A Liquidity). Financing outflows dropped sharply to $12.6M in H1 2026 from $201.5M in H1 2025 (which included $201.3M 2025 Notes repayment), though H1 2026 included $305.7M new 2032 Notes issuance, $262.9M 2028 Notes repayment, $28.7M capped call premiums, and $25.0M share repurchases (10-Q 2026-06-30, MD&A Liquidity; Consolidated Statements of Cash Flows). Ending cash fell to $145.5M at June 2026 from $159.6M at December 2025 (10-Q 2026-06-30, Consolidated Balance Sheets).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Total assets declined from $1.638B (Dec 2024) to $1.360B (Dec 2025) to $1.352B (Jun 2026), primarily from cash reduction ($367.0M → $159.6M → $145.5M) due to 2025 Notes repayment and 2026 financing activities (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Total liabilities fell from $735.7M to $523.3M (2025 Notes removal) but rose to $566.5M by Jun 2026 on new 2032 Notes ($374.2M convertible debt vs $341.9M) and higher current liabilities ($105.9M vs $88.3M) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Stockholders' equity eroded consistently: $902.3M → $836.6M → $785.7M, driven by accumulated deficit growth and a $25.0M treasury stock addition in H1 2026 (10-K 2025-12-31, Consolidated Statements of Stockholders' Equity; 10-Q 2026-06-30, Consolidated Statements of Stockholders' Equity; Consolidated Balance Sheets). Working capital declined from $294.8M (Dec 2024) to $288.0M (Dec 2025) to $275.6M (Jun 2026) (10-K 2025-12-31, MD&A Liquidity; 10-Q 2026-06-30, MD&A Liquidity). Goodwill stable at ~$524M; intangible assets declined from $339.7M to $286.5M to $271.3M on amortization and impairments (10-K 2025-12-31, Consolidated Balance Sheets; Note 7; 10-Q 2026-06-30, Consolidated Balance Sheets).

6. Data Gaps

• Quarterly standalone periods beyond Q2 and YTD (Q1 2026, Q3 2025, Q4 2025) not fully presented in provided filings; would need 10-Qs for 2026-03-31, 2025-09-30, 2025-12-31 (if filed) for complete quarterly trend.
• Revenue disaggregation by test type (clinical vs. pharma, MRD vs. NGS) not provided in tabular form for quarterly periods.
• Free cash flow (operating cash flow less capex) not explicitly disclosed; capex for H1 2026 stated as $13.2M in MD&A but not in cash flow statement line items.
• Detailed maturity profile of 2032 Convertible Notes (conversion price, terms) not in provided excerpts.
• Full 2026 annual results unavailable; trajectory assessment limited to H1 2026 vs H1 2025 and FY 2023–2025 annuals.